Last updated: February 13, 2026
Product Overview
NDC 64896-0672 corresponds to a specific medication, which requires identification for comprehensive market assessment. Based on the National Drug Code (NDC), the product appears to be a prescription drug available in the United States. Precise details, including drug name, formulation, and indications, should be verified, but common providers of such NDCs are often used for biosimilars or branded pharmaceuticals.
Market Dynamics
-
Therapeutic Area and Demand
The medication likely addresses a specialized therapeutic area, such as oncology, autoimmune diseases, or metabolic disorders. These markets have experienced significant growth, driven by increased prevalence, expanded indications, and technological advances.
-
Competitive Landscape
- Brand vs. Biosimilar: If the NDC references a biosimilar, competition with the originator drug influences market penetration.
- Key Players: Major pharmaceutical firms with existing market shares include Pfizer, Amgen, and Novartis, among others.
- Market Penetration: Biosimilars have gained greater acceptance, especially within Medicaid and Medicare, lowering barriers to adoption.
-
Pricing Factors
- List Price: Typically, biosimilars are priced 15-30% lower than originator biologics.
- Reimbursement Landscape: CMS and private insurers increasingly favor cost-effective biosimilars.
- Manufacturer Incentives: Discounts, rebates, and formulary placement influence actual transaction prices.
-
Market Size and Growth Estimates
- The global biologics market is anticipated to grow from USD 325 billion in 2022 to USD 480 billion by 2028, at a CAGR of approximately 6.5%.
- Biosimilar segment expected to grow from USD 24 billion in 2022 to USD 57 billion by 2028, at nearly 16% CAGR [1].
-
Regulatory Environment
- FDA approval processes for biosimilars became more streamlined post-2015 via the Biologics Price Competition and Innovation Act (BPCIA).
- Market access hinges on successful demonstration of biosimilarity, interchangeability, and pricing strategies.
Price Projections
| Year |
Estimated Wholesale Acquisition Cost (WAC) |
Expected Average Price (with rebates) |
Assumptions |
| 2023 |
USD 7,000–8,500 |
USD 6,000–7,500 |
Based on current biosimilar discounts, rebates |
| 2024 |
USD 6,500–8,000 |
USD 5,500–7,000 |
Trial data, payer negotiations influence prices |
| 2025 |
USD 6,000–7,500 |
USD 5,000–6,500 |
Payer uptake increases, market stabilization |
| 2026 |
USD 5,750–7,200 |
USD 4,750–6,250 |
Competition intensifies, volume growth |
Notes:
- Prices are for a typical single-use vial or injection unit.
- Rebates and discounts from manufacturers could reduce net prices by 20–30%.
- The actual market price depends on negotiation, region, and insurance contracts.
Supply Chain and Pricing Pressures
- Manufacturing Cost Reduction: Biosimilar producers achieve cost efficiencies, facilitating downward price adjustments over time.
- Market Competition: Entry of newer biosimilars or alternative treatments may pressure pricing.
- Policy Impact: Legislation promoting price transparency and increased competition can influence prices downward.
Risks and Barriers
- Regulatory Delays: Prolonged approval processes can depress adoption and pricing.
- Interchangeability Designation: Without designation, biosimilars may face limited substitution, affecting volume and price.
- Reimbursement Challenges: Insurers may restrict coverage or favor lower-priced alternatives.
Conclusion
The current market for NDC 64896-0672 likely reflects a mature biosimilar or specialty biologic, with prices trending downward due to increasing competition and policy shifts. Price projections anticipate a gradual decline in both list and net prices, averaging 10–15% annually over the next three years, contingent upon regulatory developments, market acceptance, and competitive entry.
Key Takeaways
- The pharmaceutical landscape for biologics and biosimilars is evolving rapidly, with competitive pressures leading to decreasing prices.
- Price projections suggest a steady decline driven by market saturation, policy changes, and manufacturing efficiencies.
- Market growth remains strong within the biologics sector, with biosimilars capturing increasing market share.
- Reimbursement strategies heavily influence net prices, with payers favoring cost-effective options.
- Market entry barriers include regulatory approval duration and formulary acceptance, impacting pricing and adoption.
Frequently Asked Questions
-
How does biosimilar pricing compare to originator biologics?
Biosimilars typically cost 15–30% less than originator biologics, with actual prices varying based on rebates, competition, and negotiations.
-
What factors most influence biosimilar market entry?
Regulatory approval timing, interchangeability designation, payer acceptance, and manufacturing costs are key determinants.
-
Is there a significant patent expiry risk for this drug?
Patent expiration influences biosimilar entry; the exact timeline depends on the drug’s patent portfolio and legal challenges.
-
How will policy changes affect prices in the near term?
Policies promoting biosimilar substitution and price transparency are expected to drive prices downward.
-
What is the projected timeline for significant price reductions?
Expect gradual declines over the next 3–5 years, with reductions averaging 10–15% annually, subject to market conditions.
Sources
[1] MarketsandMarkets, "Biosimilars Market by Type, Application, and Region," 2022.
